ScholarDeck

ObservationalMedicina (Kaunas, Lithuania) · 2026

Real-World Faricimab for Treatment-Naïve Neovascular AMD and Diabetic Macular Edema: 24-Month Outcomes from a Single-Center Pilot Cohort in South-Eastern Europe.

Maja L J Živković, Marko Zlatanović, Nevena Zlatanović … Mihailo Jovanović

OphthalmologyObservational

Real-world faricimab was linked to large central foveal thickness reduction in wet macular degeneration

Real-World Faricimab for Treatment-Naïve Neovascular AMD and Diabetic Macular Edema: 24-Month Outcomes from a Single-Center Pilot Cohort in South-Eastern Europe.

Maja L J Živković … Mihailo Jovanović

Medicina (Kaunas, Lithuania) · 2026

Background

Real-world data on treatment-naïve patients managed with fixed-interval maintenance protocols, particularly from South-Eastern Europe, remain limited.

Purpose

This pilot study evaluated 24-month outcomes of intravitreal faricimab in treatment-naïve nAMD and diabetic macular edema, using a standardized four-injection loading phase followed by fixed every-16-week (Q16W) maintenance.

Methods

This study conducted a retrospective, observational, single-center pilot cohort study of 20 consecutive treatment-naïve eyes (9 nAMD, 11 diabetic macular edema).

n = 20 eyes

Results

eye scans showed the retina's fluid-swelling layer growing notably thinner

MD 186.90 (95% CI 148.10 to 236)

CI excludes the null - significant

More results

All 20 eyes completed 24-month follow-up.

In diabetic macular edema, central foveal thickness decreased by 197.7 ± 65.7 µm (39.3%; 95% CI 162.5-237.3; p < 0.001; d = 3.01), and BCVA improved by 4.55 ± 1.04 lines (~23 ETDRS letters; 95% CI 4.00-5.09; p < 0.001; d = 4.39).

More results

All 20 eyes (100%) achieved ≥ 3 Snellen lines gain and ≥20% central foveal thickness reduction; 80% reached final BCVA ≥ 7 lines.

A linear mixed-effects model showed a significant time effect ( p < 0.001) but no time × group interaction (central foveal thickness p = 0.84; BCVA p = 0.51), indicating concordant trajectories across diseases.

“

Conclusion · 1 of 2

In this small, single-center, treatment-naïve pilot cohort, a fixed Q16W faricimab maintenance schedule with discretionary additional injections was associated with durable anatomical and functional improvements over 24 months in both nAMD and diabetic macular edema, with no adverse events recorded across 215 injections.

Conclusion · 2 of 2

Given the limited sample, these findings should be regarded as hypothesis-generating.

Post

Real-World Faricimab for Treatment-Naïve Neovascular AMD and Diabetic Macular Edema: 24-Month Outcomes from a Single-Center Pilot Cohort in South-Eastern Europe.

Real-world faricimab was linked to large central foveal thickness reduction in wet macular degeneration

Related papers